Company Performance Metrics
- Gary Shope: Co-Founder and CEO
- Justin Wright: Co-Founder, Executive Vice President and Bioinformaticist
Contamination Source Identification revolutionizes the standard of diagnostics by providing an RNA sequencing test for tick-borne diseases, such as Lyme disease.
CSI contributes to the delivery of patient care by providing physicians with accurate active pathogen identification to enable confident disease diagnosis and targeted treatment decisions
that encompass all infective pathogens and any contributing factors. With faster identification turn-around times and state-of-the-art equipment, CSI improves physicians’ ability to deliver accurate treatment earlier, preventing the disease from developing additional symptoms and long-term effects.